BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Galapagos NV (GLPG.BR) Business Update


11/16/2012 8:56:10 AM

MECHELEN, BELGIUM--(Marketwire - November 16, 2012) - Galapagos NV (EURONEXT BRUSSELS: GLPG) announces today that third quarter 2012 operational and financial results were in line with management expectations. Management confirms the 2012 financial guidance given earlier this year:group revenues of EUR150 million, sustained operational and net profitability, and a year-end cash position of at least EUR130 million by the end of 2012.

GLPG0634 Phase 2a results

Galapagos announced that a second Phase 2A clinical trial with GLPG0634 repeated the excellent safety of the drug, as well as the significant clinical improvements to rheumatoid arthritis (RA) patients within 4 weeks. Statistically significant improvements were seen for DAS28, HAQ-DI, ACR and CRP for the 300mg dose. The results enable Galapagos to move rapidly into Phase 2B clinical studies in early 2013. GLPG0634 is the first selective JAK1 inhibitor to potentially treat multiple autoimmune diseases, such as RA. In February 2012, Galapagos and Abbott announced a global collaboration for GLPG0634 to treat RA and other autoimmune diseases.

Tax ruling on Abbott collaboration

Galapagos received a positive ruling from the Belgian tax authorities on the collaboration agreement with Abbott. Galapagos may exempt 80% of qualifying income, based on the Galapagos patents covering JAK1 inhibitor GLPG0634, from Belgian corporate income tax. This will result in an effective income tax rate of under 5% for Galapagos for this income.

Initiation of Phase I study with GLPG0974

In October, Galapagos started its second Phase I clinical study with GLPG0974, a GPR43 inhibitor being developed to treat chronic neutrophil-driven inflammatory conditions such as inflammatory bowel disease (IBD). In this clinical study, the safety and tolerability of GLPG0974 will be evaluated for 2 weeks in 32 healthy volunteers. Aim of the study is also to confirm the strong biomarker signal and the once-daily (QD) dosing of the compound after 14 days. Results of the study are expected to be reported early next year.

Shareholder notifications

The Capital Group Companies gave notification of a holding of 1,554,436 Galapagos shares, which represents 5.8% of Galapagos' shares outstanding today. Johnson & Johnson notified that it indirectly held 2,350,061 Galapagos shares through Tibotec-Virco and Crucell, which represents 8.8% of Galapagos' shares outstanding today. .

Outlook

Management reiterates the full-year 2012 guidance given earlier in the year: The service operations are expected to increase further their cash and profit contribution in 2012. Management guides for at least EUR150 million in revenues, sustained operational and net profitability, and a year-end cash position of at least EUR130 million by the end of 2012.

About Galapagos

Galapagos (EURONEXT BRUSSELS: GLPG) (PINKSHEETS: GLPYY) is a mid-size clinical stage biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action. The Company is progressing its JAK1 inhibitor GLPG0634, as well as one of the largest pipelines in biotech, with four programs in development and over 30 discovery programs. The Galapagos Group has over 800 employees and operates facilities in six countries, with global headquarters in Mechelen, Belgium. More info at: www.glpg.com


This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Galapagos NV via Thomson Reuters ONE

[HUG#1658224]



CONTACT

Elizabeth Goodwin
Director Investor Relations
Tel: +31 6 2291 6240
Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES